Gammagard Liquid (Immune Globulin Infusion) is a medication made from human plasma that contains antibodies. It helps strengthen the immune system to fight infections. In this trial, it is given intravenously to protect multiple myeloma patients from infections while they receive cancer therapy. The medication is commonly used to treat various immune deficiency conditions and is being tested here as a preventive treatment.

B-Cell Maturation Antigen×CD3 Bispecific Antibody is a type of cancer therapy that helps the immune system fight multiple myeloma cells. This antibody therapy works by connecting immune cells (T-cells) to cancer cells, enabling the immune system to better recognize and destroy the cancer cells. It’s a targeted therapy specifically designed for multiple myeloma treatment.

Multiple Myeloma – A type of blood cancer that develops in plasma cells, which are white blood cells that help fight infections. In this condition, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells. These abnormal cells produce large amounts of defective antibodies that can build up in the body. The disease can weaken bones and affect the body’s ability to fight infections. Multiple myeloma often develops gradually and can affect various parts of the body.

Secondary Immunodeficiency – A condition where the immune system becomes weakened due to an outside cause, such as disease or medical treatment. This condition develops after birth and results in decreased ability to fight infections. The immune system’s capacity to protect against harmful organisms becomes compromised, making the person more susceptible to various infections. Secondary immunodeficiency can occur as a consequence of other medical conditions or treatments.